8-K: Utah Medical Products Reports Mixed Q2/H1 2025 Results Amid PendoTECH Sales Decline and Strong Domestic Growth

Utah Medical Products, Inc. reported second quarter and first half 2025 financial results largely consistent with projections, marked by a significant decline in sales to its biopharma OEM customer PendoTECH, offset by robust domestic sales growth and a strong balance sheet.

Summary

• Consolidated total revenues for Q2 2025 were $9,953,000, a 4.3% decrease from Q2 2024, and for H1 2025 were $19,663,000, a 9.6% decrease from H1 2024.
• The decline in sales was primarily driven by a continued decrease in sales to PendoTECH, accounting for 71% of the Q2 decline and 86% of the H1 decline; PendoTECH sales were $196,000 in Q2 2025 (down from $511,000 in Q2 2024) and $265,000 in H1 2025 (down from $2,056,000 in H1 2024).
• Domestic sales, excluding PendoTECH, increased by 7.6% in H1 2025 to $11,184,000 compared to $10,396,000 in H1 2024.
• Sales of the Filshie Clip System in the U.S. increased by 8% in Q2 2025 to $1,107,000 and by 3% in H1 2025 to $2,146,000.
• Direct domestic sales of other devices grew by 10% in Q2 2025 to $4,047,000 and by 11% in H1 2025 to $7,962,000.
• International sales (OUS) were lower than expected, totaling $4,088,000 in Q2 2025 and $8,215,000 in H1 2025 (a 15.5% decrease from H1 2024).
• Gross Profit Margin contracted to 56.2% in Q2 2025 (from 60.1% in Q2 2024) and 56.6% in H1 2025 (from 59.9% in H1 2024), primarily due to Ireland operations' unfavorable product mix, lower sales, higher raw material costs, and intercompany finished goods inventory reserve.
• Operating Income (OI) decreased by 7.1% in Q2 2025 to $3,196,000 and by 13.3% in H1 2025 to $6,349,000, but was partially offset by lower U.S. litigation costs.
• Net Income (NI) was $3,048,000 in Q2 2025 (down 11.7%) and $6,089,000 in H1 2025 (down 17.8%), impacted by lower OI, lower net non-operating income, and a higher estimated average income tax provision rate (20.5% in Q2 2025 vs 18.0% in Q2 2024; 20.9% in H1 2025 vs 17.8% in H1 2024).
• Diluted Earnings Per Share (EPS) decreased by 4.0% to $0.939 in Q2 2025 and by 10.3% to $1.858 in H1 2025, with the decline significantly mitigated by share repurchases.
• The balance sheet remains strong with no debt; Cash and Investments were $82,179,000 at June 30, 2025, a slight decline from $82,976,000 at December 31, 2024, after significant share repurchases and dividend payments.
• The company repurchased $6,709,000 of common stock (119,255 shares at an average price of $56.26) in H1 2025 and $3,488,000 (64,988 shares at an average price of $53.67) in Q2 2025.
• Dividends paid to stockholders totaled $2,018,000 ($0.305/share) in H1 2025, representing 33% of Net Income.
• The current ratio at June 30, 2025, was very strong at 41.9, up from 25.6 at December 31, 2024.

Sentiment

Score: 6

Explanation: While revenue and net income declined, the company's overall results were largely consistent with its beginning-of-year projections, indicating managed expectations. The strong balance sheet, significant share repurchases, and growth in core domestic product lines are positive indicators. The PendoTECH sales decline, though substantial, was anticipated. However, the contraction in gross profit margins and weaker international sales are areas of concern.

Positives

• Balance sheet remains very strong with no debt and a high current ratio of 41.9 at June 30, 2025.
• Significant share repurchases totaling $6.7 million in H1 2025 helped to significantly mitigate the decline in EPS relative to Net Income.
• Domestic sales, excluding the impact of PendoTECH, increased by 7.6% in H1 2025, indicating strength in core U.S. medical device markets.
• Sales of the Filshie Clip System in the U.S. increased by 8% in Q2 2025 and 3% in H1 2025.
• Direct domestic sales of other devices increased by 10% in Q2 2025 and 11% in H1 2025.
• U.S. litigation costs were $355,000 lower in Q2 2025 and $791,000 lower in H1 2025 compared to the prior year periods.
• The non-cash Femcare Identifiable Intangible Asset (IIA) amortization expense, which has reduced Operating Income by approximately $2 million per year, will be fully amortized in Q1 2026, potentially boosting future profitability metrics.

Negatives

• Consolidated total revenues declined by 4.3% in Q2 2025 and 9.6% in H1 2025 compared to the prior year periods.
• Sales to the previously largest biopharmaceutical OEM customer, PendoTECH, continued to decline significantly, representing 71% of the Q2 revenue decline and 86% of the H1 revenue decline.
• Gross Profit Margin contracted more than expected in Q2 2025 (56.2% vs 60.1% in Q2 2024) and H1 2025 (56.6% vs 59.9% in H1 2024), primarily due to issues in Ireland operations including unfavorable product mix and lower sales absorbing less fixed manufacturing overhead costs.
• International sales (OUS) were lower than expected, with direct sales to end-users declining across multiple regions including Ireland (21.5% lower), Canada (22.5% lower), UK (5.4% lower), Australia/New Zealand (39.8% lower), and France (17.2% lower) in Q2 2025.
• Net Income declined by 11.7% in Q2 2025 and 17.8% in H1 2025.
• The average consolidated income tax provision rate increased to 20.5% in Q2 2025 (from 18.0% in Q2 2024) and 20.9% in H1 2025 (from 17.8% in H1 2024).
• Lower interest rates and cash balances due to share repurchases resulted in approximately $332,000 less interest income in H1 2025 compared to H1 2024.

Risks

• Global economic conditions could impact financial performance.
• Market acceptance of products may not meet expectations.
• Regulatory approvals of products could be delayed or denied.
• Regulatory intervention in current operations poses a risk.
• Government intervention in healthcare and the economy, such as tariffs and tax reforms, could negatively affect the company.
• The company's ability to efficiently manufacture, market, and sell products is crucial for sustained performance.
• Cybersecurity threats could disrupt operations or compromise data.
• Foreign currency exchange rate fluctuations can impact reported financial results.

Future Outlook

The company expects PendoTECH sales in the second half of 2025 to be about $200,000 lower than in the second half of 2024, resulting in a full-year 2025 decline of approximately $2 million compared to 2024, which is consistent with beginning-of-year projections. Management's beginning-of-year EBITDA target of $17-$18 million continues to look achievable. The non-cash amortization expense related to the Femcare acquisition will be fully amortized in the first quarter of 2026.

Management Comments

• Overall beginning-of-year projections for financial results were consistent with actual performance.
• Management's beginning-of-year EBITDA target of $17-$18 million continues to look achievable.
• The company retains the strong desire and financial ability for repurchasing its shares at a price it believes is attractive for remaining stockholders.

Industry Context

The filing highlights a challenging period for Utah Medical Products, particularly within its biopharma OEM segment due to a significant decline in sales to PendoTECH, a previously major customer. This suggests potential shifts or consolidation within the biopharmaceutical supply chain. Conversely, the company demonstrated resilience and growth in its core domestic medical device sales, specifically with the Filshie Clip System and other direct-to-facility devices, indicating continued demand in women's and infant healthcare. International operations faced headwinds, including pressure from Canadian medical facilities to avoid U.S. purchases and the threat of reciprocal tariffs, reflecting broader geopolitical and trade challenges impacting global medical device distribution and supply chain logistics.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results for direct industry benchmarking.

Legal Proceedings

• U.S. litigation costs were $355,000 lower in Q2 2025 compared to Q2 2024, and $791,000 lower in H1 2025 compared to H1 2024, indicating a reduction in legal expenses.

Stakeholder Impact

• Shareholders: Received $2,018,000 ($0.305/share) in dividends in H1 2025. The company repurchased $6,709,000 of common stock in H1 2025, which helped mitigate the decline in EPS and demonstrates management's confidence in the stock's value.
• Employees: Non-qualified option awards totaling 24,600 shares were made to 47 employees in November 2024.
• Customers: Sales to the major OEM customer PendoTECH declined significantly, while domestic direct sales to user facilities and distributors for other medical devices showed strong growth. International customers faced potential impacts from reciprocal tariffs and pressure from medical facilities to avoid U.S. purchases.

Next Steps

• The Femcare Identifiable Intangible Asset (IIA) non-cash amortization expense will be fully amortized in Q1 2026.

Key Dates

Recommendation

While Utah Medical Products faces revenue headwinds from a significant OEM customer and some international markets, these challenges appear to be largely anticipated and managed, as indicated by results being 'consistent with overall beginning-of-year projections.' The company maintains a very strong balance sheet with no debt, actively repurchases shares, and shows robust growth in its core domestic product lines. The upcoming full amortization of the Femcare IIA in Q1 2026 will also provide a future boost to operating income. However, the overall revenue decline and the 'more than expected' contraction in gross profit margins, particularly from Ireland operations, warrant a cautious approach. A 'hold' recommendation is appropriate, suggesting investors monitor for a clear turnaround in top-line growth and sustained margin improvement before considering a 'buy' position.

Keywords

Utah Medical Products, UTMD, Medical Devices, Financial Results, Earnings, Revenue, Profit, Balance Sheet, Share Repurchase, Dividends, PendoTECH, Filshie Clip System, Biopharma, OEM, Healthcare, Q2 2025, H1 2025